Opus Genetics, Inc. Cash Flow Statement
IRD|7 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Opus Genetics, Inc. used $26M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2013 | FY2011 |
|---|---|---|---|---|---|---|---|
| Net Income | -$57.5M | -$10.0M | $17.9M | -$56.7M | -$24.6M | -$625.1K | -$2.9M |
| Depreciation & Amortization | $10.0K | $6.0K | $4.0K | $4.0K | $8.0K | $42.4K | $41.6K |
| Operating Cash Flow | -$25.6M | -$1.1M | $14.3M | -$19.4M | -$6.8M | -$6.6M | -$5.1M |
| Share Buybacks | - | - | - | - | - | $28.4K | $0 |